Related content

Editorial: Dietary Habits, Pharmacogenomics and Treatment of Diabetes and its Complications: Where do we Stand?

By  

Current Pharmaceutical Design, Vol. 20, Iss. 22, 2014-05 ,pp. : 3607-3609

Bentham Science Publishers

Access to resources Recommend Favorite

Where does adefovir stand amongst newly developed antivirals: from pharmacology to virology

By Thibault Vincent  

Future Virology, Vol. 1, Iss. 5, 2006-09 ,pp. : 553-565

Future Medicine

Access to resources Recommend Favorite

Breast cancer pharmacogenomics: where we are going

By Newman William G   Flockhart Dave  

Pharmacogenomics, Vol. 13, Iss. 6, 2012-04 ,pp. : 629-631

Future Medicine

Access to resources Recommend Favorite

Rhetoric and Hype: Where’s the ‘Ethics’ in Pharmacogenomics?

By Williams-Jones B.   Corrigan O.P.  

American Journal of PharmacoGenomics, Vol. 3, Iss. 6, 2003-01 ,pp. : 375-383

Adis International

Access to resources Recommend Favorite

Statins in Heart Failure—Where Do We Stand?

By Lyons Kristopher   McVeigh Gary   Harbinson Mark  

Cardiovascular Drugs and Therapy, Vol. 25, Iss. 1, 2011-02 ,pp. : 99-104

Springer Publishing Company

Access to resources Recommend Favorite